BXRX Baudax Bio

Baudax Bio to Present at the NobleCon Pain Management Investor Forum

Baudax Bio to Present at the NobleCon Pain Management Investor Forum

MALVERN, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that management will give a corporate presentation followed by a question and answer session at the NobleCon Pain Management Investor Forum being held virtually on Thursday, October 7, 2021.

The presentation will be made available to registered attendees (cost free) for on-demand listening beginning Thursday, October 7, 2021 at 11:00 a.m. Eastern Time and may be accessed on the “Events” page within the investors section of the Baudax Bio website at . The recording will be archived as part of its C-Suite Series at .

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit .

CONTACTS:

Investor Relations Contact:

Argot Partners

Sam Martin / Claudia Styslinger

(212) 600-1902

Media Contact:

Argot Partners

David Rosen

(212) 600-1902



EN
05/10/2021

Underlying

BXRXBaudax Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Baudax Bio

 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces Corporate Update

Baudax Bio Announces Corporate Update Company Poised to Initiate TI-168 Clinical Development Following Recent Shareholder Approval of Corporate Actions Related to TeraImmune Acquisition Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024 MALVERN, Pa., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking...

October 18, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for T...

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinic...

September 28, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio to Participate in the H.C. Wainwright Global Investment Con...

Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference MALVERN, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-1...

September 7, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces Distribution of Series C Preferred Stock to Holde...

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock MALVERN, Pa., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par va...

August 23, 2023 1 EN
 PRESS RELEASE
Free
BXRX BAUDAX BIO

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At...

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules MALVERN, Pa., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (Nasdaq: BXRX), a biotechnology company focused on developing T cell receptor therapies utilizing human regulatory T cells, as well as a portfolio of clinical stage Neuromuscular Blocking Agents and an associated reversal agent, today announced that it has entered into definitive agreements for the purchase and sale of 2,006,544 shares of its common stock and 1,395,243 Series E pre-funded warra...

August 17, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch